- ISIN
- US1374041093
- CUSIP
- 137404109
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jul 27, 2021
Highlights
- Market Cap
- $548.78M
- Enterprise Value
- $356.20M
- EPS (TTM)
- -$0.97
- Gross Profit (TTM)
- -$600.00K
- EBITDA (TTM)
- -$71.64M
- Year Range
- $4.35 - $9.27
- Target Price
- $15.00
- ROA (TTM)
- -26.95%
- ROE (TTM)
- -39.43%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
CADL Performance Chart
Candel Therapeutics, Inc. (CADL) is up 55.8% since the beginning of the year. At $9 per share, CADL is trading 5.1% below its 52-week high of $9.
Loading charts...
Returns By Period
Candel Therapeutics, Inc. (CADL) has returned 55.75% so far this year and 53.04% over the past 12 months.
Candel Therapeutics, Inc.
- 1D
- 4.51%
- 1M
- 16.87%
- YTD
- 55.75%
- 6M
- 75.30%
- 1Y
- 53.04%
- 3Y*
- 79.17%
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.74%
- 1M
- 4.90%
- YTD
- 10.35%
- 6M
- 10.28%
- 1Y
- 26.52%
- 3Y*
- 20.83%
- 5Y*
- 12.30%
- 10Y*
- 13.66%
CADL Monthly Returns History
Based on dividend-adjusted daily data since Jul 27, 2021, CADL's average daily return is +0.36%, while the average monthly return is +6.37%. At this rate, an investment would double in approximately 0.9 years.
Historically, 45% of months were positive and 55% were negative. The best month was Apr 2024 with a return of +346.2%, while the worst month was Jan 2022 at -45.1%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 4 months.
On a daily basis, CADL closed higher 47% of trading days. The best single day was Apr 4, 2024 with a return of +281.0%, while the worst single day was Dec 13, 2024 at -31.1%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 3.36% | -10.10% | -6.67% | 26.12% | 34.30% | 6.02% | 55.75% | ||||||
| 2025 | -18.55% | 26.94% | -37.05% | -13.10% | 11.00% | -7.16% | 27.37% | -10.16% | -11.92% | 5.49% | -11.34% | 18.45% | -34.91% |
| 2024 | -11.56% | 43.08% | -15.05% | 346.20% | 26.24% | -30.34% | -4.35% | 13.83% | 2.67% | -23.81% | -10.89% | 84.48% | 490.48% |
| 2023 | 43.55% | -29.95% | -25.00% | -4.44% | 17.05% | -16.56% | -14.29% | 12.96% | -24.59% | -2.18% | -0.10% | 63.52% | -17.88% |
| 2022 | -45.14% | -3.96% | 23.54% | -29.67% | 5.31% | -14.06% | -4.32% | 11.94% | -9.51% | -38.22% | -9.79% | 2.29% | -77.11% |
| 2021 | 8.43% | 5.93% | 34.83% | 3.60% | -7.75% | -24.52% | 11.71% |
Benchmark Metrics
Candel Therapeutics, Inc. has an annualized alpha of 113.30%, beta of 1.17, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since July 28, 2021.
- This stock captured 2.99% of S&P 500 Index gains and tended to rise during its downturns (downside capture of -26.11%) - a profile typical of hedging or uncorrelated assets.
- R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 113.30%
- Beta
- 1.17
- R²
- 0.01
- Upside Capture
- 2.99%
- Downside Capture
- -26.11%
Return for Risk
Risk / Return Rank
CADL ranks 65 for risk / return — better than 65% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Candel Therapeutics, Inc. (CADL) and compare them to S&P 500 Index.
| CADL | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.51 | ||
| Sortino ratioReturn per unit of downside risk | -1.52 | ||
| Omega ratioGain probability vs. loss probability | 1.18 | 1.41 | -0.22 |
| Calmar ratioReturn relative to maximum drawdown | 1.44 | 2.93 | -1.49 |
| Martin ratioReturn relative to average drawdown | 2.54 | 13.52 | -10.99 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Candel Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Candel Therapeutics, Inc. was 94.33%, occurring on Nov 3, 2023. Recovery took 132 trading sessions.
The current Candel Therapeutics, Inc. drawdown is 37.14%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2023 bear market2023 | -94.33%Nov 2023 | 2y 7d | 6mo 14d | 2y 6moOct 2021 - May 2024 |
2024 bear market2024 | -72.86%Nov 2024 | 6mo 3d | — | 2y 19dMay 2024 - now |
2021 bear market2021 | -36.31%Sep 2021 | 11d | 1mo 6d | 1mo 17dSep 2021 - Oct 2021 |
2021 bear market2021 | -31.95%Aug 2021 | 7d | 19d | 26dAug 2021 - Sep 2021 |
2021 pullback2021 | -1.57%Jul 2021 | 0s | 1d | 1dJul 2021 - Jul 2021 |
Drawdown Indicators
| CADL | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -94.33% | -56.78% | -37.55% |
Max Drawdown (1Y)Largest decline over 1 year | -37.04% | -9.10% | -27.94% |
Max Drawdown (3Y)Largest decline over 3 years | -72.86% | -18.90% | -53.96% |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -37.14% | -0.74% | -36.40% |
Average DrawdownAverage peak-to-trough decline | -62.79% | -10.72% | -52.07% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 20.98% | 1.97% | +19.01% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Candel Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Candel Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for CADL in comparison with other companies in the Biotechnology industry. Currently, CADL has a P/B value of 4.0. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with CADL
Add Candel Therapeutics, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with CADL